All In Biotech

Drugs by condition

Drugs approved for coronary artery disease and heart attack

Brand-name prescription drugs and biologics whose FDA label lists coronary artery disease and heart attack as an approved use. Matched on the label phrases: "coronary artery disease", "myocardial infarction", "acute coronary syndrome".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

112

Still marketed, NDA or BLA

Drug classes

23

Novel drugs

49

New molecular entities and new biologics

In development

20

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for coronary artery disease and heart attack.

  • Qlonilik (Clonidine Hydrochloride) · Cmp Dev LLC Jul 29, 2026
  • Baxfendy (Baxdrostat) · Astrazeneca Ab NovelPriority reviewMay 15, 2026
  • Javadin (Clonidine Hydrochloride) · Azurity Oct 23, 2025
  • Lopressor (Metoprolol Tartrate) · Xtm Consulting Aug 28, 2025
  • Sdamlo (Amlodipine Besylate) · Brillian Pharma Jul 24, 2025

All approved drugs for coronary artery disease and heart attack, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 624 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Thiazide Diuretic (9)

  • Inzirqo Hydrochlorothiazide · Novitium Pharma · 2025
  • Tribenzor Amlodipine Besylate, Hydrochlorothiazide, Olmesartan Medoxomil · Cosette · 2010
  • Exforge Hct Amlodipine Besylate, Hydrochlorothiazide, Valsartan · Novartis · 2009
  • Benicar Hct Hydrochlorothiazide, Olmesartan Medoxomil · Cosette · 2003
  • Micardis Hct Hydrochlorothiazide, Telmisartan · Boehringer Ingelheim · 2000
  • Atacand Hct Candesartan Cilexetil, Hydrochlorothiazide · Ani Pharms · 2000
  • Diovan Hct Hydrochlorothiazide, Valsartan · Novartis · 1998
  • Hyzaar Hydrochlorothiazide, Losartan Potassium · Organon · 1995
  • Zestoretic Hydrochlorothiazide, Lisinopril · Almatica · 1989

Nitrate Vasodilator (6)

Radioactive Diagnostic Agent (4)

Angiotensin 2 Receptor Blocker (4)

  • Avapro Irbesartan · Sanofi Aventis US · 1997
  • Prexxartan Valsartan · Carmel Biosciences · 2017
  • Exforge Amlodipine Besylate, Valsartan · Novartis · 2007
  • Diovan Valsartan · Novartis · 2001

GLP-1 Receptor Agonist (3)

  • Trulicity Dulaglutide · Eli Lilly and CO · 2014
  • Victoza Liraglutide · Novo Nordisk INC · 2010
  • Ozempic Semaglutide · Novo · 2019

Aldosterone Antagonist (3)

  • Inspra Eplerenone · Upjohn · 2002
  • Carospir Spironolactone · Cmp Dev LLC · 2017
  • Aldactazide Hydrochlorothiazide, Spironolactone · Pfizer · 1961

Thiazide-like Diuretic (3)

  • Hemiclor Chlorthalidone · Prm Pharma · 2025
  • Edarbyclor Azilsartan Kamedoxomil, Chlorthalidone · Azurity · 2011
  • Thalitone Chlorthalidone · Casper Pharma LLC · 1988

Adenosine Triphosphate-Citrate Lyase Inhibitor (2)

  • Nexlizet Bempedoic Acid, Ezetimibe · Esperion Theraps INC · 2020
  • Nexletol Bempedoic Acid · Esperion Theraps INC · 2020

PCSK9 Inhibitor (2)

  • Praluent Alirocumab · Regeneron Pharmaceuticals · 2015
  • Repatha Evolocumab · Amgen INC · 2021

P2Y12 Platelet Inhibitor (2)

Radiographic Contrast Agent (2)

Dihydropyridine Calcium Channel Blocker (2)

Endothelin Receptor Antagonist (1)

  • Tryvio Aprocitentan · Idorsia · 2024

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (1)

  • Mounjaro Tirzepatide · Eli Lilly and CO · 2022

Nonsteroidal Mineralocorticoid-Receptor Antagonist (1)

  • Kerendia Finerenone · Bayer Hlthcare · 2021

Factor Xa Inhibitor (1)

  • Xarelto Rivaroxaban · Janssen Pharms · 2011

Gadolinium-based Contrast Agent (1)

  • Gadavist Gadobutrol · Bayer Hlthcare · 2011

alpha-Adrenergic Blocker (1)

  • Coreg Carvedilol · Waylis Therap · 1995

HMG-CoA Reductase Inhibitor (1)

  • Zocor Simvastatin · Organon · 1991

beta-Adrenergic Blocker (1)

Alkaloid (1)

  • Lodoco Colchicine · Agepha Pharma Fz · 2023

Dietary Cholesterol Absorption Inhibitor (1)

  • Vytorin Ezetimibe, Simvastatin · Organon · 2004

Class not listed in FDA's data (60)

Drugs in development for coronary artery disease and heart attack

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

  • ZiltivekimabPhase 34 trials

    Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure

  • MilvexianJNJ-70033093, BMS-986177Phase 33 trials

    Johnson & Johnson (Janssen) · Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome

  • PacibekitugTOUR006, PAC001Phase 33 trials

    Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases

  • ezetimibe FDCPhase 32 trials

    NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic

  • EA-230hourPhase 31 trial

    EBI Anti Sepsis BV · Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)

  • FDY-5301Phase 31 trial

    Faraday Pharmaceuticals, Inc. · Acute Myocardial Infarction, STEMI, Percutaneous Coronary Revascularization

  • XTR00499mTechnicium Sestamibi, Procedure: Coronary angiographyPhase 31 trial

    Sinotau Pharmaceutical Group · Coronary Artery Disease(CAD)

  • Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction

  • SGC001Phase 22 trials

    Beijing Sungen Biomedical Technology Co., Ltd · Acute Anterior ST-Segment Elevation Myocardial Infarction, Acute Pancreatitis

  • SRSD107Phase 22 trials

    Sirius Therapeutics Co., Ltd. · Venous Thromboembolism, Coronary Artery Disease (CAD), Peripheral Arterial Disease

  • YN001Phase 22 trials

    Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease

  • A195Phase 21 trial

    XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)

  • HeXell-2020Phase 21 trial

    Hexun Biosciences Co., LTD. · Coronary Artery Disease

  • OrticumabMLDL1278a, BI204Phase 21 trial

    Abcentra · Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation

  • RBD1119Phase 21 trial

    Ribocure Pharmaceuticals AB · Stable Coronary Artery Disease

  • RBD4059Phase 21 trial

    Ribocure Pharmaceuticals AB · Stable Coronary Artery Disease CAD

  • RTP-026Phase 21 trial

    ResoTher Pharma · ST Elevation Myocardial Infarction

  • XC001Phase 21 trial

    XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)

  • YMI024Phase 21 trial

    Novartis · Coronary Artery Disease

4 discontinued brand-name drugs whose label still names it

More on coronary artery disease and heart attack: recruiting trials · published research

Related in cardiovascular and metabolic: Type 2 diabetes · Type 1 diabetes · Obesity and weight management · High blood pressure (hypertension) · Heart failure · High cholesterol · High triglycerides · Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Stroke prevention

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.